Introducing the GEMINI II study
For people with thalassaemia or low-risk MDS

**WHAT is the study?**
The GEMINI II study is a clinical trial testing an experimental medicine called SLN124. The aim is to learn the effects of SLN124 in people with thalassaemia or myelodysplastic syndrome (MDS), whose bodies produce fewer healthy red blood cells than normal and who can store too much iron in their bodies.

**WHY is it being carried out?**
Specifically, the research team wants to find the most effective and safe dose of SLN124, which can then be used in larger research studies in the future to understand how safe the medicine is and how well it works. The study will compare the effect of SLN124 with a placebo (a substance that is known to have no effect on the body).

**WHO can take part?**
Adults aged 18 or older with non-transfusion-dependent alpha- or beta-thalassaemia or low-risk or very low-risk MDS. Your doctor can tell you more about the other requirements that are needed to take part in the study, such as certain blood test results.

**SLN124** is a gene ‘silencing’ therapy – one that is designed to temporarily block a specific gene’s message. SLN124 aims to temporarily ‘silence’ TMPRSS6, a gene in the liver. It is hoped that silencing TMPRSS6 will increase hepcidin, a hormone that controls iron levels in the body. As hepcidin increases, iron levels in the blood are expected to decrease. This could in turn allow more healthy red blood cells to be produced and improve anaemia.

**WHERE is it taking place?**
GEMINI II is a global study that will enrol approximately 112 participants at up to 25 trial sites, spanning 9 countries in Europe, the Middle East and Southeast Asia.

**WHEN does it begin?**
Recruitment is currently open. If you are interested in taking part, your doctor or nurse can tell you more information. If you decide to take part, you can expect to attend an initial screening visit to check that you are eligible. The study will take place for a minimum of 4 and a maximum of 12 months, depending on when you joined. During this time, you will attend follow up visits roughly every month for health checks and to receive further doses of medicine – your first appointment may be within a few weeks.

**HOW can I find out more?**
Speak to your doctor about whether the study may be appropriate for you. You can also contact the study sponsor Silence Therapeutics via patient-info@silence-therapeutics.com for more information.

Silence Therapeutics is involved in the discovery, development and delivery of new short interfering ribonucleic acid (siRNA) medicines for the treatment of diseases with significant unmet medical need.

Date of preparation: February 2021